Search
Filter Results
- Resource Type
- Article1
- Journal1
- Journal Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Comparative Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Arch Gen Psychiatry1
Search Results
Sort by
- JournalDigital Access HathiTrust v. 1-28, 1880-1907.
- ArticleJanowsky DS, Leichner P, Parker D, Judd L, Huey L, Clopton P.Arch Gen Psychiatry. 1978 Nov;35(11):1384-9.Intravenously administered methylphenidate, 0.5 mg/kg, causes a consistent rise in human serum growth hormone level, with peak values usually occurring 30 minutes after infusion. This rise is attenuated in patients receiving various antipsychotic medications administered on a long-term basis and is decreased in schizophrenic and drug-dependent patients. Methylphenidate causes increases in talkativeness, blood pressure, and pulse that generally parallel increases in serum growth hormone level. However, in contrast to the methylphenidate-induced rise in serum growth hormone level, methylphenidate-induced changes in cardiovascular variables and talkativeness are not altered by antipsychotic medications or diagnostic classification.